A prospective and observational study on rationale use of noradrenalin and vasopressin in critically ill patients

Kalyan Sapkota, Abhishek Sinha, Sonaxi Agrahari, Shibi Mary Thomas, Balakeshwa RamaiahInternational Journal of Basic & Clinical Pharmacology 2024 · DOI

Abstract

Shock, particularly septic shock, remains a critical medical condition with high mortality rates due to inadequate blood flow and subsequent multi-organ failure. This prospective observational study evaluated the rationale use of noradrenaline and vasopressin in 50 critically ill patients. Septic shock was the most prevalent diagnosis (68%), primarily driven by lower respiratory tract infections and urosepsis. Results indicated significant improvements in blood pressure, particularly diastolic pressure when vasopressin was used. Furthermore, significant reductions in serum lactate, C-reactive protein (CRP), and troponin were observed, suggesting improved tissue perfusion and reduced systemic inflammation without significant adverse drug interactions.

Introduction

Shock is a life-threatening condition where insufficient blood flow leads to cellular dysfunction and organ failure. Septic shock, the most severe form, carries a staggering mortality rate of 50-75%. While fluid resuscitation and antibiotics are foundational treatments, vasopressors like noradrenaline (norepinephrine) and vasopressin are essential for maintaining hemodynamic stability. This study aims to evaluate the clinical application and efficacy of these vasopressors in a real-world tertiary care setting, focusing on their impact on blood pressure and biochemical markers of physiological stress.

Methods

This prospective observational study was conducted at a tertiary care hospital from January to October 2023. The cohort included 50 critically ill patients admitted to the ICU, HICU, or CCU diagnosed with septic, cardiogenic, or hypovolemic shock. Patients were treated with noradrenaline, vasopressin, or a combination of both. Exclusion criteria included pregnancy, breastfeeding, and patients undergoing dialysis. Data collection encompassed demographics, drug dosages, treatment duration, and laboratory parameters including arterial blood gas (ABG), serum lactate, CRP, troponin, and potassium levels.

Results

The study population was 58% male and 42% female, with the 61-70 age group being the most represented (24%). Septic shock was the dominant diagnosis, accounting for 68% of cases.

Diagnostic distribution and causes of shock in the study cohort.

Lower respiratory tract infections (LRTI) were the leading cause of shock (23.4%), followed by urosepsis (19.14%). Hemodynamic monitoring revealed distinct trends for each vasopressor. Patients receiving noradrenaline reached a mean systolic blood pressure of approximately 110 mmHg by day six. Those on vasopressin experienced a steady rise in diastolic blood pressure, increasing from an initial 63.20 mmHg to 70 mmHg by day five.

Trends in systolic and diastolic blood pressure over six days of treatment.

The overall patient outcome was positive for the majority, with 62% of patients being discharged following clinical improvement. However, the severity of the underlying conditions resulted in a 24% mortality rate.

Discussion

The findings highlight the efficacy of norepinephrine as a primary vasopressor and the potential benefits of combination therapy. The 16% of patients who received both norepinephrine and vasopressin showed more stable and prominent increases in diastolic blood pressure, suggesting a synergistic hemodynamic effect.

Crucially, the study observed significant decreases in serum lactate, C-reactive protein (CRP), and troponin levels. These biochemical shifts indicate that the vasopressor therapy successfully addressed the underlying pathophysiology by improving tissue oxygenation and reducing systemic inflammation and cardiac strain. Safety was also a key finding; no significant fluctuations in potassium levels or adverse drug interactions were noted, supporting the standard clinical use of these agents.

Conclusion

This study demonstrates that the rational use of noradrenaline and vasopressin significantly improves hemodynamic parameters in critically ill patients with shock. The observed reduction in inflammatory and cardiac biomarkers underscores the systemic benefits of effective vasopressor therapy. While limited by a small sample size and single-center design, these results provide a foundation for larger multi-center trials to further refine therapeutic strategies for shock management.

Summary updated

Abstract

Background: Shock, particularly septic shock, is a critical medical condition characterized by inadequate blood flow, leading to multi-organ failure and high mortality rates. Traditional treatment includes fluid resuscitation and antibiotic therapy, but advancements in understanding and management are needed. This study aims to evaluate the rationale use of noradrenalin and vasopressin in patients with shock, specifically focusing on their effects on blood pressure. Methods: Conducted as a prospective observational study at a tertiary care hospital, the study involved 50 critically ill patients diagnosed with septic, cardiogenic or hypovolemic shock. Patients were treated with either noradrenalin, vasopressin or both and data were collected from ICU, HICU and CCU admissions. Inclusive criteria included critically ill patients with shock on noradrenalin or vasopressin. Exclusion criteria included pregnant or breastfeeding women and dialysis patients. Results: Among the patients, septic shock was the most common type (68%). Age distribution showed a majority (24%) aged 61-70 years, while a minority (2%) was 11-20 years old. Significant contributors to septic shock were lower respiratory tract infections (23.4%) and urosepsis (19.4%). The study noted fluctuations in systolic and diastolic blood pressures in response to the medications. Conclusions: The study result demonstrated that the change in the blood pressure were significant. Changes in the diastolic pressure when used vasopressin along with norepinephrine was more prominent. Drug interactions didn’t cause any adverse effects in the course of treatment as there is no significant fluctuation in the K levels. Not much difference was seen in blood cells count, ABG but significant decrease in serum lactate, CRP and troponin were seen.
BibTeX
@article{sapkota2024prospective,
  author = {Kalyan Sapkota and Abhishek Sinha and Sonaxi Agrahari and Shibi Mary Thomas and Balakeshwa Ramaiah},
  title = {{A prospective and observational study on rationale use of noradrenalin and vasopressin in critically ill patients}},
  journal = {International Journal of Basic \& Clinical Pharmacology},
  year = {2024},
  doi = {10.18203/2319-2003.ijbcp20243842},
}
Figure